Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMMODRE)

Drug Name

ND-2110 Drug Info

Synonyms

CHEMBL3361254; 2-[(3~{R})-12-(4-morpholin-4-ylcyclohexyl)oxy-7-thia-9,11-diazatricyclo[6.4.0.0^{2,6}]dodeca-1(8),2(6),9,11-tetraen-3-yl]ethanamide; ND-2110; GTPL8082; SCHEMBL15228032; SCHEMBL10344171; BDBM50040806; ZINC299825077; 2-[(3R)-12-{[(1r,4r)-4-(morpholin-4-yl)cyclohexyl]oxy}-7-thia-9,11-diazatricyclo[6.4.0.0(2),]dodeca-1(12),2(6),8,10-tetraen-3-yl]acetamide

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 68115559
TTD Drug ID: DMMODRE

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Renal carcinoma antigen NY-REN-64 (IRAK-4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GS-5718	DMRKU0L	Rheumatoid arthritis	FA20	Phase 2	[3]
Zabedosertib	DMEZGWP	Atopic dermatitis	EA80	Phase 2	[4]
CA-4948	DMWV8C6	Lymphoma	2A80-2A86	Phase 1	[5]
BAY1834845	DM8V62T	Psoriasis vulgaris	EA90	Phase 1	[6]
AZD6793	DM5GRZV	Inflammation	1A00-CA43.1	Phase 1	[7]
SAR444656	DMIF2OL	Atopic dermatitis	EA80	Phase 1	[8]
Pyrazolopyrimidine and thienopyrimidine amide derivative 1	DM6TB4Z	N. A.	N. A.	Patented	[9]
Pyrazolopyrimidine and thienopyrimidine amide derivative 2	DMFUNH4	N. A.	N. A.	Patented	[9]
Indazoletriazolephenyl derivative 1	DMHJDU6	N. A.	N. A.	Patented	[9]
Indazoletriazolephenyl derivative 2	DMWZLK6	N. A.	N. A.	Patented	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Renal carcinoma antigen NY-REN-64 (IRAK-4)	TTKFVXR	IRAK4_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8082).
2	Recent advances in the discovery of small molecule inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4) as a therapeutic target for inflammation and oncology disorders. J Med Chem. 2015 Jan 8;58(1):96-110.
3	IRAK4 degrader to take on innate immunity. Nat Biotechnol. 2020 Nov;38(11):1221-1223.
4	Oral IRAK4 inhibitor BAY-1834845 prevents acute respiratory distress syndrome. Biomed Pharmacother. 2022 Sep;153:113459.
5	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7	Clinical pipeline report, company report or official report of AstraZeneca
8	Clinical pipeline report, company report or official report of Sanofi
9	Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32.